NEUROCRINE BIOSCIENCES INC

NBIX · NASDAQ

Updated at 2026-11-16 23:35:16

$165.31-1.24%
Today's High
$168.62
Today’s Low
$164.81
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price & Market Data
Search empty state illustration
...

Candlestick trends are for reference. Refer to the trading page for actual data.

Key Statistics

Previous Open
$169.96
Previous Close
$167.40
Volume
1.38M
Market Cap
$16.94B
P/E Ratio
24.11X
EPS
$6.74

Previous Day Range

$164.64$171.16

52-Week Range

$122.14$186.12

Company Overview

Sector
HEALTHCARE
Industry
Biotechnology
Sub-industry
DRUG MANUFACTURERS - SPECIALTY & GENERIC
Headquarters
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, UNITED STATES, 92130
Country
US
Listing Date
1996-05-23
Fiscal Year End
December
Shares Outstanding
101.65M
CIK
0000914475

Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.

Financial Metrics

Revenue

2026-09-30

$1.12B

2026-06-30

$959M

2026-03-31

$814.5M

2025-12-31

$805.5M

Operating Expenses

2026-09-30

$764.8M

2026-06-30

$782.8M

2026-03-31

$614.7M

2025-12-31

$577M

Net Income

2026-09-30

$206.5M

2026-06-30

$144.4M

2026-03-31

$197.9M

2025-12-31

$153.7M

Net Profit Margin

2026-09-30

18.39%

2026-06-30

15.05%

2026-03-31

24.29%

2025-12-31

19.08%

Earnings Per Share

2026-09-30

$2.78

2026-06-30

$2.36

2026-03-31

$1.94

2025-12-31

$1.88

Earnings Before Interest, Taxes, Depreciation, and Amortization

2026-09-30

$328M

2026-06-30

$189.9M

2026-03-31

$193.3M

2025-12-31

$235.4M

Effective Tax Rate

2026-09-30

27.21%

2026-06-30

10.97%

2026-03-31

19.81%

2025-12-31

35.79%

FAQs

Risk Warning

Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.